TOP TEN perturbations for NM_000293 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000293
Selected probe(set): 202738_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000293 (202738_s_at) across 5392 perturbations tested by GENEVESTIGATOR:

zalypsis study 2 / untreated OPM1 cell sample

Relative Expression (log2-ratio):-2.8719158
Number of Samples:2 / 2
Experimental zalypsis study 2
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control untreated OPM1 cell sample
OPM1 multiple myeloma cells untreated.

F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):-2.4672804
Number of Samples:4 / 6
Experimental F. tularensis study 1 (novicida)
Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

PMA; ionomycine study 2 / unstimulated CD4 memory T-cell sample

Relative Expression (log2-ratio):-2.2583332
Number of Samples:8 / 8
Experimental PMA; ionomycine study 2
CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 ?g/ml). ATC code:---
Control unstimulated CD4 memory T-cell sample
Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects.

F. tularensis study 1 (tularensis Schu S4) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):-2.2308512
Number of Samples:4 / 6
Experimental F. tularensis study 1 (tularensis Schu S4)
Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):2.074871
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):2.0568066
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS5)
CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

polyamide study 1 (match) / dexamethasone study 8

Relative Expression (log2-ratio):-2.0453777
Number of Samples:3 / 3
Experimental polyamide study 1 (match)
Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS, 4mM penicillin/streptomycin and a synthetic DNA-binding polyamide (targeting the consensus sequence of the glucocorticoid receptor element and binding the glucocorticoid-induced zipper GILZ). After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours.
Control dexamethasone study 8
Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS and 4mM penicillin/streptomycin. After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours. ATC code:, , , , , , , , , ,

polyamide study 1 (match) / vehicle (medium) treated A549 cell sample

Relative Expression (log2-ratio):-2.025672
Number of Samples:3 / 3
Experimental polyamide study 1 (match)
Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS, 4mM penicillin/streptomycin and a synthetic DNA-binding polyamide (targeting the consensus sequence of the glucocorticoid receptor element and binding the glucocorticoid-induced zipper GILZ). After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours.
Control vehicle (medium) treated A549 cell sample
Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS and 4mM penicillin/streptomycin. Samples were taken after additional 56 hours.

B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)

Relative Expression (log2-ratio):1.9828615
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal B-cell; 20uM)
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

polyamide study 1 (match) / mifepristone study 4

Relative Expression (log2-ratio):-1.9622078
Number of Samples:3 / 3
Experimental polyamide study 1 (match)
Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS, 4mM penicillin/streptomycin and a synthetic DNA-binding polyamide (targeting the consensus sequence of the glucocorticoid receptor element and binding the glucocorticoid-induced zipper GILZ). After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours.
Control mifepristone study 4
Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS, 4mM penicillin/streptomycin and 3?M of the glucocorticoid receptor antagonist mifepristone. After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours. ATC code: